People: Targacept Inc (TRGT.O)
27 Apr 2015
Dr. Stephen A. Hill, M.D. has been appointed as President, Chief Executive Officer, Director of Targacept, Inc., effective December 1, 2012. From May 2012 to November 2012, Dr. Hill served as president and chief executive officer of QUE Oncology, a start-up biotechnology company, and, from March 2011 to December 2011, he served as president and chief executive officer of 21st Century Biodefense, Inc., a biodefense company. From April 2008 until its acquisition in December 2010, he served as president and chief executive officer of Solvay Pharmaceuticals, Inc., a pharmaceutical company. Prior to Solvay, he served as president, chief executive officer and director of ArQule, Inc., a pharmaceutical company, from April 1999 to March 2008. Dr. Hill is a member of the board of directors of the publicly-traded companies Cellectar Biosciences, Inc. (formerly Novelos Therapeutics, Inc.) and Lipocine, Inc.
|Total Annual Compensation, USD||Long-Term Incentive Plans, USD||All Other, USD||Fiscal Year Total, USD|